UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules

Simpson, AB; Calvert, PM; Sludden, JA; Boddy, AV; Griffin, MJ; Schatzlein, A; Wilson, P; ... Twelves, CJ; + view all (2002) Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. ANN ONCOL , 13 (3) 399 - 402. 10.1093/annonc/mdf041.

Full text not available from this repository.

Abstract

Background Topotecan and cisplatin combinations have shown schedule-dependent toxicity. which may in part be due to cisplatin nephrotoxicity. As carboplatin is less nephrotoxic and increasingly replacing cisplatin in clinical practice, the aim of this study was to define the optimal sequence and dose for topotecan in combination with carboplatin.Patients and methods: Two parallel phase I trials, with pharmacokinetic studies, were conducted administering carboplatin on day I with topotecan on days 1-5 (schedule A) or days 8-12 (schedule B), repeated every 3 weeks.Results: Twenty-one patients were treated over two dose levels, carboplatin AUC 4 [glomerular filtration rate (GFR) calculated from Cr-51-EDTA clearance] with topotecan 0.5 or 0.75 mg/m(2). At the first dose level, six patients were evaluable for each schedule. With schedule A, from 34 cycles, there were two dose reductions and 10 treatment delays due to myelosuppression. With schedule B from 25 cycles, there was one reduction and 10 delays. At dose level 2, both patients in schedule A had dose-limiting neutropenia. In contrast, there was no dose-limiting toxicity with schedule B in six patients, although the majority of cycles were delayed.Conclusion: The combination of topotecan and carboplatin using these 3-weekly schedules lead to significant myelotoxicity with attendant dose reductions and delays; the optimal scheduling of these agents remains to be defined.

Type: Article
Title: Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules
DOI: 10.1093/annonc/mdf041
Keywords: carboplatin, chemotherapy, topotecan, IMPAIRED RENAL-FUNCTION, CISPLATIN, PHARMACOKINETICS
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > SoP Pharmaceutical and Bio Chemistry
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/351947
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item